Repare Therapeutics Inc (RPTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Repare Therapeutics Inc stock (RPTX) is currently trading at $2.65. Repare Therapeutics Inc PS ratio (Price-to-Sales) is 9.62. Analyst consensus price target for RPTX is $3.00. WallStSmart rates RPTX as Sell.
- RPTX PE ratio analysis and historical PE chart
- RPTX PS ratio (Price-to-Sales) history and trend
- RPTX intrinsic value — DCF, Graham Number, EPV models
- RPTX stock price prediction 2025 2026 2027 2028 2029 2030
- RPTX fair value vs current price
- RPTX insider transactions and insider buying
- Is RPTX undervalued or overvalued?
- Repare Therapeutics Inc financial analysis — revenue, earnings, cash flow
- RPTX Piotroski F-Score and Altman Z-Score
- RPTX analyst price target and Smart Rating
Repare Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Repare Therapeutics Inc (RPTX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Repare Therapeutics Inc (RPTX) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
64.15% held by institutions, strong professional interest
Supporting Valuation Data
Repare Therapeutics Inc (RPTX) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -76.70%, a shrinking business
Very expensive at 9.6x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Repare Therapeutics Inc (RPTX) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.99) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (9.62) suggest expensive pricing. Growth concerns include Revenue Growth at -76.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -49.80%, Operating Margin at -3.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -49.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -76.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RPTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RPTX's Price-to-Sales ratio of 2.14x trades at a deep discount to its historical average of 654.67x (28th percentile). The current valuation is 100% below its historical high of 9004.87x set in Mar 2021, and 151% above its historical low of 0.85x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~0.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Repare Therapeutics Inc (RPTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Repare Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 12M with 77% decline year-over-year.
Key Findings
Generating 3M in free cash flow and 3M in operating cash flow. Earnings are translating into actual cash generation.
Spending 63% of revenue (8M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 77% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Repare Therapeutics Inc.
Bottom Line
Repare Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Repare Therapeutics Inc(RPTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Repair Therapeutics Inc., a precision oncology company, discovers and develops novel therapies using its synthetic lethality approach in Canada and the United States. The company is headquartered in Montral, Canada.